检索结果 - L Rimsky
- Showing 1 - 15 results of 15
-
1
-
2
-
3
-
4
Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies 由 L Rimsky, Johan Vingerhoets, Veerle Van Eygen, Joseph J. Eron, Bonaventura Clotet, Annemie Hoogstoel, Katia Boven, Gastón Picchio
出版 2011Artigo -
5
-
6
-
7
The HIV-1 Reverse Transcriptase M184I Mutation Enhances the E138K-Associated Resistance to Rilpivirine and Decreases Viral Fitness 由 Rima Kulkarni, Kerim Babaoglu, E.B. Lansdon, L Rimsky, Veerle Van Eygen, Gastón Picchio, Evguenia S. Svarovskaia, Michael D. Miller, Kirsten L. White
出版 2011Artigo -
8
TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1 由 Hilde Azijn, Ilse Tirry, Johan Vingerhoets, Marie‐Pierre de Béthune, Guenter Kraus, Katia Boven, Dirk Jochmans, Elke Van Craenenbroeck, Gastón Picchio, L Rimsky
出版 2009Artigo -
9
Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial 由 Anton Pozniak, Javier O Morales-Ramirez, Elly Katabira, Dewald Steyn, Sergio Lupo, Mario Santoscoy, Beatriz Grinsztejn, Kiat Ruxrungtham, L Rimsky, Simon Vanveggel, Katia Boven
出版 2009Artigo -
10
-
11
Stimulation of the human immunodeficiency virus type 1 enhancer by the human T-cell leukemia virus type I tax gene product involves the action of inducible cellular proteins 由 Ernst Böhnlein, Miriam Siekevitz, Dean W. Ballard, John W. Lowenthal, L Rimsky, Hal P. Bogerd, J A Hoffman, Yuji Wano, B. Robert Franza, Warner C. Greene
出版 1989Artigo -
12
-
13
Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment‐naïve, HIV‐1‐infected patients 由 Cal Cohen, Jean‐Michel Molina, Pedro Cahn, Bonaventura Clotet, Jan Fourie, Beatriz Grinsztejn, Wei Hao, Margaret Johnson, K Supparatpinyo, HM Crauwels, L Rimsky, Simon Vanveggel, Paige Williams, Katia Boven
出版 2010Artigo -
14
Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials 由 Calvin Cohen, Jean‐Michel Molina, Isabel Cassetti, Ploenchan Chetchotisakd, Adriano Lazzarin, Chloe Orkin, Frank S. Rhame, Hans-Jürgen Stellbrink, Taisheng Li, Herta Crauwels, L Rimsky, Simon Vanveggel, Peter Williams, Katia Boven
出版 2012Artigo -
15
Efficacy and Safety of Rilpivirine (TMC278) Versus Efavirenz at 48 Weeks in Treatment-Naive HIV-1–Infected Patients 由 Calvin Cohen, Jean‐Michel Molina, Pedro Cahn, Bonaventura Clotet, Jan Fourie, Beatriz Grinsztejn, Hao Wu, Margaret Johnson, Michael S. Saag, Khuanchai Supparatpinyo, Herta Crauwels, Éric Lefebvre, L Rimsky, Simon Vanveggel, Peter Williams, Katia Boven
出版 2012Artigo
相关主题
Virology
Biology
Gene
Antiretroviral therapy
Genetics
Human immunodeficiency virus (HIV)
Viral load
Reverse-transcriptase inhibitor
Efavirenz
Internal medicine
Medicine
Rilpivirine
Molecular biology
Lentivirus
Viral disease
Virus
Biochemistry
Drug resistance
Immunology
Polymerase chain reaction
Reverse transcriptase
Adverse effect
Antibody
Antigen
Cell biology
Computer science
Etravirine
Mutant
Nevirapine
Randomized controlled trial